PPARG and metabolic dysfunction-associated steatohepatitis: Activation of PPARγ has been shown to ameliorate NASH in preclinical models by reducing hepatic inflammation, oxidative stress, and insulin resistance (Huang et al. 2025; Li et al. 2022; Singh et al. 2024).